Treace Medical Concepts (TMCI) CFO reports Form 4 insider stock deal

Rhea-AI Filing Summary

Treace Medical Concepts, Inc. Chief Financial Officer reports an insider stock transaction. On 01/10/2026, Mark Hair reported an "F" code transaction involving 8,719 shares of common stock at a reported price of $0 per share. Following this transaction, he beneficially owned 510,245 shares of Treace Medical Concepts common stock in direct form. A noted portion of this position consists of 398,009 restricted stock units, which typically represent share-based awards that may settle in stock over time.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hair Mark

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	8,719	$0.00	--

Holdings After Transaction: Common Stock — 510,245 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hair Mark

(Last) (First) (Middle)

C/O TREACE MEDICAL CONCEPTS, INC.

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA FL 32081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/10/2026		F		8,719	D	$0	510,245(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 398,009 restricted stock units.

	/s/ Lisa Taylor as Attorney-in-fact for Mark Hair	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TMCI's CFO report?

Treace Medical Concepts Chief Financial Officer Mark Hair reported an insider transaction in the companys common stock dated 01/10/2026, coded as an "F" transaction involving 8,719 shares at a reported price of $0 per share.

How many TMCI shares were involved in the CFOs latest Form 4 filing?

The Form 4 filing shows that 8,719 shares of Treace Medical Concepts, Inc. common stock were reported in the transaction dated 01/10/2026.

How many TMCI shares does the CFO own after this transaction?

After the reported transaction, Chief Financial Officer Mark Hair beneficially owned 510,245 shares of Treace Medical Concepts common stock in direct ownership, according to the filing.

What portion of the CFOs TMCI holdings are restricted stock units?

The filing states that the reported holdings include 398,009 restricted stock units, which form part of Chief Financial Officer Mark Hairs overall beneficial ownership in Treace Medical Concepts.

What is the relationship of the reporting person to Treace Medical Concepts (TMCI)?

The reporting person, Mark Hair, is identified as an officer of Treace Medical Concepts, Inc., serving as the companys Chief Financial Officer and is not listed as a director or 10% owner in this filing.

Is the insider transaction reported by TMCIs CFO a direct or indirect holding?

The Form 4 indicates that the 510,245 shares of Treace Medical Concepts common stock beneficially owned following the transaction are held in direct (D) ownership by the reporting person.